Affymax Valuation
| AFFY Stock | USD 0.0008 0.0006 42.86% |
Affymax seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of Affymax from analyzing the firm fundamentals such as return on equity of 1.12, and Profit Margin of 73.00 % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Affymax's price fluctuation is out of control at this time. Calculation of the real value of Affymax is based on 3 months time horizon. Increasing Affymax's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Affymax is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Affymax Pink Sheet. However, Affymax's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.0E-4 | Real 0.001063 | Hype 7.03E-4 | Naive 0.001077 |
The intrinsic value of Affymax's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Affymax's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Affymax helps investors to forecast how Affymax pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Affymax more accurately as focusing exclusively on Affymax's fundamentals will not take into account other important factors: Affymax Total Value Analysis
Affymax is presently forecasted to have valuation of (512.26 K) with market capitalization of 2.61 M, debt of 0, and cash on hands of 3.4 M. The negative valuation of Affymax may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Affymax fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(512.26 K) | 2.61 M | 0 | 3.4 M |
Affymax Investor Information
The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Affymax last dividend was issued on the 28th of November 2014. Based on the key measurements obtained from Affymax's financial statements, Affymax is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Affymax Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Affymax has an asset utilization ratio of 18.39 percent. This suggests that the Company is making $0.18 for each dollar of assets. An increasing asset utilization means that Affymax is more efficient with each dollar of assets it utilizes for everyday operations.Affymax Profitability Analysis
The company reported the previous year's revenue of 1.37 M. Net Loss for the year was (14.42 M) with loss before overhead, payroll, taxes, and interest of (10.49 M).About Affymax Valuation
Our relative valuation model uses a comparative analysis of Affymax. We calculate exposure to Affymax's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Affymax's related companies.Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York. Affymax operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
8 Steps to conduct Affymax's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Affymax's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Affymax's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Affymax's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Affymax's revenue streams: Identify Affymax's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Affymax's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Affymax's growth potential: Evaluate Affymax's management, business model, and growth potential.
- Determine Affymax's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Affymax's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Affymax Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Quarterly Earnings Growth Y O Y | -0.537 | |
| Retained Earnings | -558.1 M |
Additional Tools for Affymax Pink Sheet Analysis
When running Affymax's price analysis, check to measure Affymax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Affymax is operating at the current time. Most of Affymax's value examination focuses on studying past and present price action to predict the probability of Affymax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Affymax's price. Additionally, you may evaluate how the addition of Affymax to your portfolios can decrease your overall portfolio volatility.